Stereotactic body radiotherapy feasibility for patients with peripheral stage Ι lung cancer and poor pulmonary function

  • Authors:
    • Aiko Koba
    • Kazuhiko Hayashi
    • Osamu Suzuki
    • Yoshifumi Kawaguchi
    • Kazuhiko Ogawa
    • Masashi Chatani
  • View Affiliations

  • Published online on: January 22, 2020     https://doi.org/10.3892/ol.2020.11333
  • Pages: 2515-2521
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to evaluate the toxicity and investigate the prognostic factors of stereotactic body radiotherapy (SBRT) for peripheral stage Ι lung cancer in patients with poor pulmonary function. Data from 95 patients with stage I lung cancer with poor pulmonary function treated using SBRT at Osaka Rosai Hospital were retrospectively analyzed. Poor pulmonary function was defined as the forced expiratory volume %/sec (FEV1/FVC) <70% or percentage of vital capacity (%VC) <80% during pretreatment spirometry testing. The median FEV1/FVC and %VC of the patients were 59.1 and 78.8%, respectively. The most commonly prescribed dose of SBRT was 50 Gy in four fractions (68 patients, 72%). The median follow‑up period was 34 months. Four patients developed adverse effects of grade ≥3, one patient developed grade 5 radiation pneumonitis, one grade 5 hemoptysis, one grade 3 radiation pneumonitis and one grade 3 chest wall pain. The 3‑year local control and overall survival (OS) rates were 78.8 and 59.9%, respectively. Univariate analysis revealed that Karnofsky performance status (KPS) significantly predicted OS (P=0.037). Thus, SBRT in patients with stage I lung cancer with poor pulmonary function may be effective with acceptable toxicity. A KPS score ≥80 indicated good prognosis.
View Figures
View References

Related Articles

Journal Cover

March-2020
Volume 19 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Koba A, Hayashi K, Suzuki O, Kawaguchi Y, Ogawa K and Chatani M: Stereotactic body radiotherapy feasibility for patients with peripheral stage Ι lung cancer and poor pulmonary function. Oncol Lett 19: 2515-2521, 2020
APA
Koba, A., Hayashi, K., Suzuki, O., Kawaguchi, Y., Ogawa, K., & Chatani, M. (2020). Stereotactic body radiotherapy feasibility for patients with peripheral stage Ι lung cancer and poor pulmonary function. Oncology Letters, 19, 2515-2521. https://doi.org/10.3892/ol.2020.11333
MLA
Koba, A., Hayashi, K., Suzuki, O., Kawaguchi, Y., Ogawa, K., Chatani, M."Stereotactic body radiotherapy feasibility for patients with peripheral stage Ι lung cancer and poor pulmonary function". Oncology Letters 19.3 (2020): 2515-2521.
Chicago
Koba, A., Hayashi, K., Suzuki, O., Kawaguchi, Y., Ogawa, K., Chatani, M."Stereotactic body radiotherapy feasibility for patients with peripheral stage Ι lung cancer and poor pulmonary function". Oncology Letters 19, no. 3 (2020): 2515-2521. https://doi.org/10.3892/ol.2020.11333